1 hour ago

$100 Invested In Ventas 5 Years Ago Would Be Worth This Much Today

Ventas VTR has outperformed the market over the past 5 years by 2.99% on an annualized basis producing an average annual return of 21.38%. Currently, Ventas has a market capitalization […]

Breaking News

Breaking news

See all

1 hour ago

Deutsche Bank plans to cut 2,000 jobs with 'signficant' branch reduction

1 hour ago

Boeing CFO worries about tariff impact on parts, says cash flow improving

1 hour ago

Boeing CFO worries about tariff impact on parts, says cash flow improving

2 hours ago

Selling My House and Pocketing $640k – Can I Avoid Capital Gains Taxes?

2 hours ago

I'm 75 and Still Working. Do I Have to Take RMDs?

2 hours ago

I'm 67 With $2M in an IRA. How Do I Make It Last for Life?

2 hours ago

Should I Convert 20% of My 401(k) to a Roth Annually to Cut Taxes and RMDs?

2 hours ago

Should I Convert 20% of My 401(k) to a Roth Annually to Cut Taxes and RMDs?

3 hours ago

Activist Starboard launches boardroom battle at Autodesk over margin concerns

News

See all

1 hour ago

$100 Invested In Ventas 5 Years Ago Would Be Worth This Much Today

1 hour ago

CLEARVIEW RESOURCES LTD. REPORTS DECEMBER 31, 2024 CORPORATE RESERVES INFORMATION AND ANNOUNCES UPDATES

1 hour ago

Unpacking the Latest Options Trading Trends in Lululemon Athletica

1 hour ago

Conestoga Capital Advisors Announces Succession Plans for Small Cap Growth Strategy

1 hour ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update

1 hour ago

Behind the Scenes of Groupon's Latest Options Trends

1 hour ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update

LOS ANGELES, March 20, 2025 /PRNewswire/ — Armata Pharmaceuticals, Inc. ARMP (“Armata” or the “Company”), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the…